Skip to main content

Table 1 Characteristics of the patients of the three sets (n = 60)

From: Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia

Patient

Sex

Age at diagnosis (years)

WBC (Count × 109/l)

Recurrent Rearrangement

Risk group

Set A

     

1

F

5

83.1

none

HR

2

F

7

21.6

none

SR

3

M

2.5

4.5

TEL/AML1

SR

4

F

1.5

1.2

none

SR

5

M

4

18.5

TEL/AML1

SR

6

F

2.5

52.5

none

HR

7

F

2

5.4

none

SR

8

F

8

0.9

none

SR

9

M

3

7.8

none

SR

10

M

3

5.4

none

SR

11

F

2

7.2

none

SR

12

F

6

18.4

TEL/AML1

SR

13

F

4

24.3

TEL/AML1

SR

14

F

5

4.5

none

SR

15

M

13

3.9

none

HR

16

F

2

3.6

none

SR

17

M

4

47

TEL/AML1

SR

18

M

10

35.8

TEL/AML1

HR

19

F

3

14.9

none

SR

20

F

14

82

none

HR

21

M

6

68

none

HR

22

F

10

150

none

HR

23

M

2

15.4

TEL/AML1

SR

24

M

3

2.9

none

SR

25

M

3

5.4

none

SR

26

F

3

41

none

SR

Set B

     

27

F

7.5

4

none

SR

28

M

6

26.2

none

SR

29

M

15

4.2

none

HR

30

F

2

2.2

none

SR

31

F

3

22.6

none

SR

32

M

2

130

TEL/AML1

HR

33

M

2.5

1.3

TEL/AML1

SR

Set C

     

34

F

9

1.4

none

SR

35

M

5

12.1

TEL/AML1

SR

36

M

1

34.3

none

SR

37

F

6

17.9

none

SR

38

M

3

3.3

none

SR

39

F

3

7.3

none

SR

40

F

6

1.9

TEL/AML1

SR

41

F

6

37.5

TEL/AML1

SR

42

M

5

4.2

none

SR

43

F

6

38.7

TEL/AML1

SR

44

F

6

2.7

none

SR

45

F

3

13

none

SR

46

M

5

1.3

none

SR

47

M

3

16.5

TEL/AML1

SR

48

M

3

6.8

TEL/AML1

SR

49

F

5

9.8

none

SR

50

M

1

6.8

none

SR

51

M

7

36.9

none

SR

52

M

2

1.6

none

SR

53

M

7

13.5

TEL/AML1

SR

54

M

9

24

none

SR

55

F

3

10.2

none

SR

56

F

6

9.3

none

SR

57

M

3

6.9

none

SR

58

M

10

96

none

HR

59

M

6

1.4

none

SR

60

M

3.5

83.6

none

HR

  1. WBC: white blood cell count; F:Female, M:Male
  2. HR and SR are respectively high risk and standard risk groups according to the FRALLE 2000 trial.
  3. • HR: age ≥ 10 years, or white blood cell count ≥ 50 × 109/l, or central nervous system involvement, or t(9;22), or t(4;11) or MLL rearrangement, or hypoploidy (≤ 44 chromosomes)
  4. • SR: 1 ≤ age < 10 years, and white blood cell count < 50 × 109/l, and no central nervous system involvement, and none of the following cytogenetic features: t(9;22), t(4,11) or MLL rearrangement, hypoploïdy
  5. TEL/AML1-positive ALL and TEL/AML1-negative ALL can be assigned to HR or SR categories, according to clinical features.